Tax withholding on ANI Pharmaceuticals (ANIP) SVP restricted stock vesting

Rhea-AI Filing Summary

ANI Pharmaceuticals SVP, Generics Ori Gutwerg had 3,314 shares of Common Stock withheld on March 7, 2026 to cover tax obligations at $74.04 per share. The shares were tied to the vesting of 6,476 restricted shares, and Gutwerg now holds 81,468 shares directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gutwerg Ori

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, GENERICS

3. Date of Earliest Transaction (Month/Day/Year)
03/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/07/2026		F(1)		3,314	D	$74.04	81,468	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 6,476 shares of restricted stock, the grant of which was previously reported.

Remarks:

	/s/ Ori Gutwerg, by attorney-in-fact Meredith W. Cook	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ANI Pharmaceuticals (ANIP) report for Ori Gutwerg?

ANI Pharmaceuticals reported that SVP, Generics Ori Gutwerg had 3,314 shares of Common Stock withheld to cover tax liabilities. The withholding was linked to the vesting of 6,476 previously granted restricted shares and was treated as a tax payment, not an open-market sale.

Was the ANI Pharmaceuticals (ANIP) Form 4 transaction a sale of shares?

No, the Form 4 shows a tax-withholding disposition, not an open-market sale. 3,314 shares were withheld under Rule 16(b)-3 in connection with the vesting of 6,476 restricted shares, effectively paying taxes using shares rather than cash.

How many ANI Pharmaceuticals (ANIP) shares does Ori Gutwerg hold after this filing?

After the tax-withholding transaction, Ori Gutwerg directly holds 81,468 shares of ANI Pharmaceuticals Common Stock. This figure reflects his position following the withholding of 3,314 shares for taxes related to the vesting of previously granted restricted stock.

What price was used for the ANI Pharmaceuticals (ANIP) tax-withholding shares?

The tax-withholding disposition used a price of $74.04 per share for 3,314 shares. This per-share value is reported in the Form 4 as the price at which shares were withheld to satisfy tax obligations arising from the restricted stock vesting.

What triggered the tax-withholding transaction reported by ANI Pharmaceuticals (ANIP)?

The transaction was triggered by the vesting of 6,476 shares of restricted stock previously granted to Ori Gutwerg. To satisfy tax obligations on that vesting, 3,314 shares were withheld, an arrangement exempt under Rule 16(b)-3 and typical for equity compensation.